These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 37545643)

  • 21. Aggresome formation and liquid-liquid phase separation independently induce cytoplasmic aggregation of TAR DNA-binding protein 43.
    Watanabe S; Inami H; Oiwa K; Murata Y; Sakai S; Komine O; Sobue A; Iguchi Y; Katsuno M; Yamanaka K
    Cell Death Dis; 2020 Oct; 11(10):909. PubMed ID: 33097688
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies.
    Cascella R; Capitini C; Fani G; Dobson CM; Cecchi C; Chiti F
    J Biol Chem; 2016 Sep; 291(37):19437-48. PubMed ID: 27445339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oxr1 improves pathogenic cellular features of ALS-associated FUS and TDP-43 mutations.
    Finelli MJ; Liu KX; Wu Y; Oliver PL; Davies KE
    Hum Mol Genet; 2015 Jun; 24(12):3529-44. PubMed ID: 25792726
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of CNC1 gene in TDP-43 aggregation-induced oxidative stress-mediated cell death in S. cerevisiae model of ALS.
    Bharathi V; Girdhar A; Patel BK
    Biochim Biophys Acta Mol Cell Res; 2021 May; 1868(6):118993. PubMed ID: 33647321
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A yeast TDP-43 proteinopathy model: Exploring the molecular determinants of TDP-43 aggregation and cellular toxicity.
    Johnson BS; McCaffery JM; Lindquist S; Gitler AD
    Proc Natl Acad Sci U S A; 2008 Apr; 105(17):6439-44. PubMed ID: 18434538
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Molecular Mechanisms Underlying TDP-43 Pathology in Cellular and Animal Models of ALS and FTLD.
    Wood A; Gurfinkel Y; Polain N; Lamont W; Lyn Rea S
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reappraisal of the anatomical spreading and propagation hypothesis about TDP-43 aggregation in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.
    Riku Y
    Neuropathology; 2020 Oct; 40(5):426-435. PubMed ID: 32157757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TDP-43 pathology: From noxious assembly to therapeutic removal.
    Keating SS; San Gil R; Swanson MEV; Scotter EL; Walker AK
    Prog Neurobiol; 2022 Apr; 211():102229. PubMed ID: 35101542
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Znf179 E3 ligase-mediated TDP-43 polyubiquitination is involved in TDP-43- ubiquitinated inclusions (UBI) (+)-related neurodegenerative pathology.
    Lee YC; Huang WC; Lin JH; Kao TJ; Lin HC; Lee KH; Lin HC; Shen CJ; Chang WC; Huang CC
    J Biomed Sci; 2018 Nov; 25(1):76. PubMed ID: 30404641
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prion-like Mechanism in Amyotrophic Lateral Sclerosis: are Protein Aggregates the Key?
    Lee S; Kim HJ
    Exp Neurobiol; 2015 Mar; 24(1):1-7. PubMed ID: 25792864
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drosha inclusions are new components of dipeptide-repeat protein aggregates in FTLD-TDP and ALS C9orf72 expansion cases.
    Porta S; Kwong LK; Trojanowski JQ; Lee VM
    J Neuropathol Exp Neurol; 2015 Apr; 74(4):380-7. PubMed ID: 25756586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A role for SUMOylation in the Formation and Cellular Localization of TDP-43 Aggregates in Amyotrophic Lateral Sclerosis.
    Maurel C; Chami AA; Thépault RA; Marouillat S; Blasco H; Corcia P; Andres CR; Vourc'h P
    Mol Neurobiol; 2020 Mar; 57(3):1361-1373. PubMed ID: 31728929
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Respiration Enhances TDP-43 Toxicity, but TDP-43 Retains Some Toxicity in the Absence of Respiration.
    Park SK; Park S; Liebman SW
    J Mol Biol; 2019 May; 431(10):2050-2059. PubMed ID: 30905713
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy.
    Fushimi K; Long C; Jayaram N; Chen X; Li L; Wu JY
    Protein Cell; 2011 Feb; 2(2):141-9. PubMed ID: 21327870
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Expression of Huntingtin and TDP-43 Derivatives in Fission Yeast Can Cause Both Beneficial and Toxic Effects.
    Marte L; Boronat S; Barrios R; Barcons-Simon A; Bolognesi B; Cabrera M; Ayté J; Hidalgo E
    Int J Mol Sci; 2022 Apr; 23(7):. PubMed ID: 35409310
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct pathways leading to TDP-43-induced cellular dysfunctions.
    Yamashita M; Nonaka T; Hirai S; Miwa A; Okado H; Arai T; Hosokawa M; Akiyama H; Hasegawa M
    Hum Mol Genet; 2014 Aug; 23(16):4345-56. PubMed ID: 24698978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An Intramolecular Salt Bridge Linking TDP43 RNA Binding, Protein Stability, and TDP43-Dependent Neurodegeneration.
    Flores BN; Li X; Malik AM; Martinez J; Beg AA; Barmada SJ
    Cell Rep; 2019 Apr; 27(4):1133-1150.e8. PubMed ID: 31018129
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wild-type human TDP-43 expression causes TDP-43 phosphorylation, mitochondrial aggregation, motor deficits, and early mortality in transgenic mice.
    Xu YF; Gendron TF; Zhang YJ; Lin WL; D'Alton S; Sheng H; Casey MC; Tong J; Knight J; Yu X; Rademakers R; Boylan K; Hutton M; McGowan E; Dickson DW; Lewis J; Petrucelli L
    J Neurosci; 2010 Aug; 30(32):10851-9. PubMed ID: 20702714
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FUS/TLS forms cytoplasmic aggregates, inhibits cell growth and interacts with TDP-43 in a yeast model of amyotrophic lateral sclerosis.
    Kryndushkin D; Wickner RB; Shewmaker F
    Protein Cell; 2011 Mar; 2(3):223-36. PubMed ID: 21452073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Elimination of TDP-43 inclusions linked to amyotrophic lateral sclerosis by a misfolding-specific intrabody with dual proteolytic signals.
    Tamaki Y; Shodai A; Morimura T; Hikiami R; Minamiyama S; Ayaki T; Tooyama I; Furukawa Y; Takahashi R; Urushitani M
    Sci Rep; 2018 Apr; 8(1):6030. PubMed ID: 29662239
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.